NeuroSolutions is a contract research organisation established in 2001 as a service provider of cutting edge electrophysiological and behavioural research in the field of neuroscience.
NeuroSolutions has established expertise in delivering first class preclinical translational research into pain, particularly around the development of new treatments into neuropathic and inflammatory pain. We have worked extensively in rodent tissue and have recently expanded our capabilities to record from non-human primate and post-mortem human tissue
In vitro: Compound action potential recording from isolated nerves, naïve and modelled, slice patch-clamp recordings, dissociated DRG patch-clamp recordings from naïve and modelled animals, in rodent, non-human primate and human tissue.
Relevant NeuroSolutions Publications:
| Disease Areas | Behavioural Tests | Electrophysiological Assays |
|---|---|---|
|
Disease Areas
|
Behavioural Tests
|
Behavioural Tests
In vivo: Single fibre recording, spontaneous and evoked, single neurone recording from the spinal cord and brain, all naïve and modelled animals In vitro: Compound action potential recording from isolated nerves, naïve and modelled, slice patch-clamp recordings, dissociated DRG patch-clamp recordings from naïve and modelled animals |
"Thank you for the absolutely phenomenal work you have done for Redpin. As biotech managers, we frequently push CROs to the max and sometimes take them for granted. After reviewing the work that you have done over the past year, I felt that I needed to let you know what a difference you had made to Redpin’s growth and success. Your work has been of the highest caliber and your dedication unmatched."
Elma Hawkins PhD, MBA, former President and CEO Redpin Therapeutics, Inc.
"I have worked with NeuroSolutions on many projects over many years. The quality of the data is second to none, their scientific expertise and collaborative approach to our technicality demanding projects has been excellent. For example, the work on SEN1576 has led to high-impact joint publications with Senexis and this compound is now being developed by Talisman Therapeutics.."
Dr Mark Treherne - As former Chief Executive of Senexis Limited (Dr Treherne is currently Chief Executive of Life Sciences Organisation at UK Trade & Investment, which helps UK business trade overseas).
Email: info@nsolns.com
Contact Head-office on +44 (0) 8454 500171
One of our partner companies may be better suited to your requirements